Characteristic Ondansetron (n = 32) Placebo (n = 33) p
Plasma GGT, U/L; mean (SD)
(reference range 8-61)
109.66
(89.71)
232.39 (491.06) t = -1.39, 63 df, p = 0.17
Plasma ALT, U/L; mean (SD)
(reference range < 41)
35.37
(26.24)
36.06 (29.98) t = -0.09, 63 df, p = 0.92
Plasma AST, U/L; mean (SD)
(reference range < 37)
33.97
(23.97)
47.58 (45.64) t = -1.50, 63 df, p = 0.14
Plasma MCV, f/L; mean (SD)
(reference range 80-100)
95.72
(8.60)
94.74 (6.43) t = 0.51, 63 df, p = 0.61
CIWA-AR, mean (SD) 13.09 (8.87) 14.24 (9.54) t = -0.50, 63 df, p = 0.62
SADD, mean (SD) 28.41 (8.61) 24.73 (6.94) t = 1.90, 63 df, p = 0.06
OCDS, mean (SD) 48.47 (8.89) 44.40 (10.09) t = 1.72, 63 df, p = 0.09
HDRS, mean (SD) 9.01 (5.07) 10.15 (5.57) t = -0.87, 63 df, p = 0.39
Biological markers were measured and instruments were applied over two weeks before the beginning of double-blind study.
GGT: Gamma-Glutamyl Transferase; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; MCV: Mean Cellular Volume; CIWA-AR: Clinical Institute Withdrawal Assessment; SADD: Short Alcohol Dependence Data; OCDS: Obsessive-Compulsive Drinking Scale; HDRS: Hamilton Depression Rating Scale.
Table 2: Baseline hepatic indices and psychometric measures between ondansetron and placebo groups.